Last reviewed · How we verify
combination of Ivabradine and bisoprolol
combination of Ivabradine and bisoprolol is a Antiarrhythmic Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Atrial fibrillation for stroke prevention, Heart failure. Also known as: concor plus procorolan.
Ivabradine works by inhibiting the I(f) channel in the sinoatrial node, reducing heart rate, while bisoprolol acts as a beta-1 selective adrenergic receptor blocker, further reducing heart rate and contractility.
Ivabradine works by inhibiting the I(f) channel in the sinoatrial node, reducing heart rate, while bisoprolol acts as a beta-1 selective adrenergic receptor blocker, further reducing heart rate and contractility. Used for Atrial fibrillation for stroke prevention, Heart failure.
At a glance
| Generic name | combination of Ivabradine and bisoprolol |
|---|---|
| Also known as | concor plus procorolan |
| Sponsor | Ain Shams University |
| Drug class | Antiarrhythmic |
| Target | I(f) channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ivabradine's mechanism of action is unique in that it specifically targets the I(f) channel, which is responsible for the pacemaker current in the sinoatrial node. This results in a reduction in heart rate without affecting contractility. Bisoprolol, on the other hand, is a beta-1 selective adrenergic receptor blocker, which means it primarily affects the heart, reducing heart rate and contractility, while minimizing effects on the lungs and other beta-2 receptors.
Approved indications
- Atrial fibrillation for stroke prevention
- Heart failure
Common side effects
- Bradycardia
- Fatigue
- Dizziness
- Headache
Key clinical trials
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " (PHASE2, PHASE3)
- Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing (PHASE4)
- Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- combination of Ivabradine and bisoprolol CI brief — competitive landscape report
- combination of Ivabradine and bisoprolol updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about combination of Ivabradine and bisoprolol
What is combination of Ivabradine and bisoprolol?
How does combination of Ivabradine and bisoprolol work?
What is combination of Ivabradine and bisoprolol used for?
Who makes combination of Ivabradine and bisoprolol?
Is combination of Ivabradine and bisoprolol also known as anything else?
What drug class is combination of Ivabradine and bisoprolol in?
What development phase is combination of Ivabradine and bisoprolol in?
What are the side effects of combination of Ivabradine and bisoprolol?
What does combination of Ivabradine and bisoprolol target?
Related
- Drug class: All Antiarrhythmic drugs
- Target: All drugs targeting I(f) channel
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Heart failure
- Also known as: concor plus procorolan
- Compare: combination of Ivabradine and bisoprolol vs similar drugs
- Pricing: combination of Ivabradine and bisoprolol cost, discount & access